IDiyas

For the Inventor, By the Inventor

Sollentuna, Sweden

Evert Homan

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 11.9

ph-index = 3

Forward Citations = 27(Granted Patents)


Company Filing History:

goldMedal5 out of 10 
 
Thomas Helledays Stiftelse for Medicinsk Forskning
 patents
silverMedal4 out of 1,970 
 
Amgen Inc.
 patents
bronzeMedal3 out of 55 
 
Biovitrum Ab
 patents
4. 1 out of 15 
 
Kancera Ab
 patents
where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...
Loading Chart...
10 patents (USPTO):
1. 12357634 - 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy (2025-07-15),
2. 11504368 - 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy (2022-11-22),
3. 10632125 - MTH1 inhibitors for treatment of inflammatory and autoimmune conditions (2020-04-28),
4. 10179790 - MTH1 inhibitors for treatment of cancer (2019-01-15),
5. 10064869 - MTH1 inhibitors for treatment of inflammatory and autoimmune conditions (2018-09-04),
6. 9233946 - Sulfonamide compounds (2016-01-12),
7. 8686011 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2014-04-01),
8. 8541592 - Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (2013-09-24),
9. 7807700 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2010-10-05),
10. 7253196 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2007-08-07),

Title: Evert Homan: Innovator in Pharmaceutical Chemistry

Introduction

Evert Homan is a notable inventor based in Sollentuna, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of therapeutic compounds. With a total of 10 patents to his name, Homan's work has the potential to impact various medical treatments.

Latest Patents

Homan's latest patents include the development of 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives. These compounds are useful in therapy for the treatment of cancers, inflammation, autoimmune diseases, and graft-versus-host diseases, particularly in transplantation patients. The patents also cover pharmaceutical compositions comprising these compounds or their salts, along with methods for preparing them.

Career Highlights

Throughout his career, Evert Homan has worked with prominent companies in the pharmaceutical industry, including Amgen Inc. and Biovitrum AB. His experience in these organizations has allowed him to refine his expertise and contribute to innovative solutions in medicine.

Collaborations

Homan has collaborated with several professionals in his field, including Martin Henriksson and Martin Scobie. These partnerships have likely enhanced his research and development efforts, leading to successful patent applications.

Conclusion

Evert Homan's contributions to pharmaceutical chemistry through his innovative patents demonstrate his commitment to advancing medical science. His work has the potential to improve treatment options for various diseases, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…